Our company
About us
About us
Leadership
Board of Directors
Strategy
Innovative approach
R&D Priorities
Intellectual Property
Partnerships
Pipeline
Pipeline
ACB2112 – potentiating ICI therapy efficacy and eligibility for all colorectal cancer patients
ACB2112 is effectively breaking immune escape
News
Publications
Contact
Contact
Full name
*
e-mail
*
Company
*
Phone
*
Message
Send
